.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Disease Spotlight: NMOSD

Managing and Treating Neuromyelitis Optica Spectrum Disorder

December 22nd 2021

An expert neurologist, advocacy director, and a pair of patients with NMOSD discuss the current landscape of the demyelinating disorder.

Brighter Spotty Lesions Show Potential in Distinguishing AQP4-NMOSD From MOGAD

December 19th 2021

These findings have clinical implications for the diagnosis of AQP4-NMOSD and in helping clinicians differentiating it from other demyelinating diseases such as MOGAD.

Outlining the Clinical and Radiological Features of NMOSD, MOGAD

December 18th 2021

Amy Kunchok, MD, staff neurologist at the Mellen Center for Multiple Sclerosis and Research at Cleveland Clinic, discussed a recent talk she gave that highlighted the different phenotypes of AQP-IgG NMOSD and MOGAD.

Clinical, Radiological Features of NMOSD and MOGAD: Amy Kunchok, MD

December 16th 2021

The staff neurologist at the Cleveland Clinic Mellen Center for Multiple Sclerosis outlined key findings from her talk at a recent Institutional Perspectives in Neurology: Multiple Sclerosis event. [WATCH TIME: 3 minutes]

New Remission Lesions Rare, May Indicate Relapse in MOGAD, AQP4-NMOSD

December 11th 2021

Results from the cohort study contrast with reports in multiple sclerosis, finding that new remission silent lesions were rare in both myelin oligodendrocyte glycoprotein antibody disease and aquaporin-4 antibody neuromyelitis optica spectrum disorder.

B-Cell Depletion and Long-Term Outcomes in NMOSD With Inebilizumab: Jeffrey Bennett, MD, PhD

December 1st 2021

The professor of neurology at the University of Colorado provided insight on the data that reinforced the relationship between B-cell depletion and improved outcomes using inebilizumab (Uplizna; Horizon Therapeutics). [WATCH TIME: 2 minutes]

Inebilizumab Efficacy Unchanged With Prior Rituximab Use in NMOSD

November 29th 2021

Annualized attack rate was reduced to 0.08 attacks per year after the first administration of inebilizumab, similar to those who were not previously exposed to rituximab.

Outer Retinal Layer Thinning Non-Factor in Retinal Damage of AQP4-IgG NMOSD

November 4th 2021

Repeated analyses using both 3-mm and 1-mm diameter macular data—narrower volumes than standard—showed no relevant outer plexiform layer or outer nuclear layer thinning in those with seropositive AQP4-IgG.

Priorities in NMO: Biomarkers, Therapy Discontinuation, and More With Marcelo Matiello, MD

October 28th 2021

The associate director of the Neuromyelitis Optica Clinic and Research Unit at Mass General spoke about some of the unmet needs and unanswered questions surrounding NMO management.

Better COVID-19 Outcomes in MOGAD Than NMOSD, Registry Data Show

October 28th 2021

Data presented at CMSC 2021 suggest worse COVID-19 outcomes were associated with patients with neuromyelitis optica spectrum disorder and other comorbidities.